ABSTRACT

Happy Nurhayati. S022008026. 2021. Meta-Analysis The Effectiveness of Using Antiplatelet Drugs Uptake in Decreasing Mortality of COVID-19 Patients. Principal adviser: Dr. Eti Poncorini Pamungkasari, dr., M.Pd. Co adviser: Prof. Bhisma Murti, dr., MPH., MSc., Ph.D. Marsters Program in Public Health, Universitas Sebelas Maret.

Background: Viscoelastic coagulation testing in COVID-19 patients often found increased concentrations of D-dimer and fibrinogen. Thrombotic complications that occur can be in the form of Venous Thromboembolism (VTE) where this thrombotic disease is one of the factors associated with increased mortality of COVID-19 patients. This study aims to analyze the effectiveness of antiplatelet drugs in reducing mortality in COVID-19 patients.

Subjects and Methods: This study is a meta-analysis study using PRISMA flowchart guidelines. The article search process was carried out between 2020-2021 using databases from PubMed, Science direct, Google Schoolar and Scopus. The article search was carried out taking into account the eligibility criteria defined in the PICO model. Population= COVID-19 patients, Intervention= using antiplatelet drugs, Comparison= not using anticoagulant drugs, Outcome= mortality. The keywords used were "antiplatelet" AND "mortality" AND "COVID-19". The research inclusion criteria used were full-text cohort papers, in English and the relationship measure used was the adjusted odds ratio (aOR). Based on the database, there were 9 articles that met the inclusion criteria. The analysis was carried out using RevMan 5.3 software.

Results: A meta-analysis was performed on 10 articles from the UK, Spain, Germany, Poland, America, Israel and China. The results of data processing showed that COVID-19 patients who received antiplatelet drugs had a 0.70 times risk of dying than those without antiplatelet drugs, this result was not statistically significant (aOR= 0.70; 95% CI= 0.46 to 1.07; p= 0.100).

Conclusion: The results of this meta-analysis concluded that in clinical practice of evidence-based medicine, the use of antiplatelet drugs cannot be used to reduce mortality in COVID-19 patients.

Keywords: antiplatelet, mortality, COVID-19